Chinese drugmaker Hangzhou Jiuyuan Gene Engineering develops biosimilar Ozempic (semaglutide) called Jiyoutai, first locally developed in China, pending approval.
Chinese drugmaker Hangzhou Jiuyuan Gene Engineering has developed a biosimilar version of Novo Nordisk's popular diabetes drug Ozempic, called Jiyoutai, and applied for its approval. If approved, Jiyoutai would be China's first locally developed biosimilar semaglutide drug, amid a global surge in demand for semaglutide that far outpaces supply. The patent for the drug is set to expire in 2026, but is currently being contested in court.
April 03, 2024
7 Articles